- Open
- 13.75
- High
- 14.00
- Low
- 13.50
- Close
- 13.79
- Change
- -0.25 (-1.82%)
- Volume
- 152,399
| 13 Jul 2026 | 07:00:10 | Update on US Phase 3 Pivotal Study |
| 1 Jul 2026 | 07:00:05 | Keynote Address at 8th Annual Photodynamic Day |
| 30 Jun 2026 | 18:15:29 | Result of AGM and voting results |
| 30 Jun 2026 | 07:00:07 | Leeds drops SSI 78% over Mupirocin with Steriwave |
| 22 Jun 2026 | 07:00:11 | Update on US Phase 3 Pivotal Study |
Ondine is dedicated to creating and bringing to market innovative antimicrobial treatments that meet critical patient requirements, are eco-friendly, offer significant public health advantages, are simple to implement, and are cost-effective compared to the infections they combat.
| 13 Jul 2026 | 07:00:10 | Update on US Phase 3 Pivotal Study |
| 1 Jul 2026 | 07:00:05 | Keynote Address at 8th Annual Photodynamic Day |
| 30 Jun 2026 | 18:15:29 | Result of AGM and voting results |
| 30 Jun 2026 | 07:00:07 | Leeds drops SSI 78% over Mupirocin with Steriwave |
| 22 Jun 2026 | 07:00:11 | Update on US Phase 3 Pivotal Study |
Ondine is dedicated to creating and bringing to market innovative antimicrobial treatments that meet critical patient requirements, are eco-friendly, offer significant public health advantages, are simple to implement, and are cost-effective compared to the infections they combat.
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £317m | +1.0% | |
| £231m | +0.1% | |
| £110m | +0.4% | |
OBIOndine Biomedical Inc | £77m | +0.0% |
| £56m | -0.4% | |
| £24m | +0.5% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £317m | +1.0% | |
| £231m | +0.1% | |
| £110m | +0.4% | |
OBIOndine Biomedical Inc | £77m | +0.0% |
| £56m | -0.4% | |
| £24m | +0.5% |